Our newly developed score model, which incorporated, in addition to patient factor sarcopenia, tumor number, tumor size, major venous thrombosis, serum AFP, and albumin into consideration, could effectively predict patient survival after TACE. This evidence concerns the gene ALB and neoplasm.